Division of Cardiology, Department of Medicine, Arrhythmia Service, University of Ottawa Heart Institute, Ottawa, ON, Canada.
J Nucl Cardiol. 2013 Apr;20(2):297-306. doi: 10.1007/s12350-012-9668-9. Epub 2013 Jan 4.
Cardiac sarcoidosis (CS) has gained significant interest in recent years with the emergence of advanced imaging modalities such as MRI and F(18)-fluorodeoxyglucose-positron emission tomography (FDG-PET) as modalities to aid in the diagnosis of this condition. CS remains a difficult condition to diagnose, particularly in cases of isolated cardiac involvement and it can present with a broad spectrum of clinical syndromes. Furthermore, the appropriate management of these patients remains controversial. FDG-PET has a potential role not only in diagnosis of CS but also in directing further therapies, facilitating the decision to start immunosuppression and monitoring the response to it. In this article, we discuss when to consider FDG-PET, outline the current optimal patient preparation and scanning protocols and then, using case examples, discuss the use of FDG-PET in follow-up of patients with known or suspected CS. We also outline how PET can influence management decisions in these patients.
近年来，随着 MRI 和 F(18)-氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）等先进成像方式的出现，心脏结节病（CS）引起了人们的极大兴趣，这些方式有助于诊断这种疾病。CS 仍然是一种难以诊断的疾病，特别是在孤立性心脏受累的情况下，它可能表现出广泛的临床综合征。此外，这些患者的适当治疗仍然存在争议。FDG-PET 不仅在 CS 的诊断中具有潜在作用，而且在指导进一步治疗方面也具有潜在作用，有助于决定开始免疫抑制治疗以及监测其反应。在本文中，我们讨论了何时考虑 FDG-PET，概述了目前最佳的患者准备和扫描方案，然后使用病例示例讨论了 FDG-PET 在已知或疑似 CS 患者随访中的应用。我们还概述了 PET 如何影响这些患者的治疗决策。
